Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Assets (2021 - 2025)

Historic Assets for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $40.9 million.

  • Verrica Pharmaceuticals' Assets rose 2420.2% to $40.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.9 million, marking a year-over-year increase of 2420.2%. This contributed to the annual value of $54.1 million for FY2024, which is 3365.69% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Assets stood at $40.9 million for Q3 2025, which was up 2420.2% from $39.1 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Assets high stood at $108.1 million for Q1 2021, and its period low was $32.9 million during Q3 2024.
  • Its 5-year average for Assets is $65.4 million, with a median of $63.4 million in 2022.
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Assets soared by 9766.82% in 2023, and later plummeted by 6610.64% in 2024.
  • Over the past 5 years, Verrica Pharmaceuticals' Assets (Quarter) stood at $80.1 million in 2021, then tumbled by 44.19% to $44.7 million in 2022, then surged by 82.46% to $81.6 million in 2023, then plummeted by 33.66% to $54.1 million in 2024, then fell by 24.45% to $40.9 million in 2025.
  • Its last three reported values are $40.9 million in Q3 2025, $39.1 million for Q2 2025, and $42.2 million during Q1 2025.